If the AF9 gene turns positive after bone marrow transplantation, it suggests the possibility of relapse.
MLL-AF9 is commonly found in acute myeloid leukemia, which has a poor prognosis and usually requires consolidation therapy after induction chemotherapy remission and can be turned negative after parallel allogeneic hematopoietic stem cell transplantation, which means that there is a possibility of cure. Chemotherapeutic agents include cytarabine and zorubicin.
However, bone marrow transplantation has a recurrence rate of about 50%. Generally, it is necessary to monitor the bone marrow microscopic residual disease, such as flow cytology monitoring, genetic testing, etc., and once there is a positive microscopic residual disease, it suggests that there is a possibility of recurrence.
It is recommended to actively contact with the competent doctor, according to the specific conditions of discretion under the guidance of the physician to carry out chemotherapy and other specialized treatment. Maintain a regular routine, eat a balanced diet, and ensure a rich intake of protein and vitamins.